Literature DB >> 18618510

Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival.

Tokujiro Yano1, Naoko Miura, Tomoyoshi Takenaka, Akira Haro, Hiroshi Okazaki, Taro Ohba, Hidenori Kouso, Takuro Kometani, Fumihiro Shoji, Yoshihiko Maehara.   

Abstract

BACKGROUND: To propose 'never-smoking nonsmall cell lung cancer (NSCLC)' as a separate entity, the clinicopathologic differences of operable NSCLC between never-smoking patients and patients with a history of smoking were investigated.
METHODS: The medical records of 1405 patients with primary NSCLC who underwent a complete resection at the study institution from 1974 through 2004 were reviewed for clinicopathologic variables and postoperative survival.
RESULTS: The proportion of never-smoking patients with NSCLC has been significantly increasing over 30 years, from 15.9% in the 1970s to 32.8% in the 2000s. A significantly greater proportion of female patients or adenocarcinoma patients was found in the 'never-smoking NSCLC' group in comparison to the 'smoking NSCLC' group (85.8% vs 11.2% and 87.8% vs 49.1%, respectively). The proportion of pathologic stage IA disease for the 'never-smoking NSCLC' group was significantly higher than that for the 'smoking NSCLC' group (40.1% vs 25.4%; P < .0001). With regard to both overall and cancer-specific survival, the 'never-smoking NSCLC' patient group was significantly superior to the 'smoking NSCLC' group. In addition to smoking status, the factors found to be significantly associated with the postoperative survival rate were sex, histologic type, T classification, and N classification by univariate analyses. A multivariate analysis revealed never-smoking status to be an independent prognostic factor in addition to pathologic T and N classification.
CONCLUSIONS: The differences in the clinicopathologic factors and survivals between the 'never-smoking NSCLC' patient group and the 'smoking NSCLC' group suggest that NSCLC in never-smokers should be considered a separate disease entity. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Year:  2008        PMID: 18618510     DOI: 10.1002/cncr.23679

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

Review 1.  Human papillomavirus and lung cancinogenesis: an overview.

Authors:  Antonio Carlos de Freitas; Ana Pavla Gurgel; Elyda Golçalves de Lima; Bianca de França São Marcos; Carolina Maria Medeiros do Amaral
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-29       Impact factor: 4.553

2.  Primary lung cancer in never smokers.

Authors:  Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2011-05-03       Impact factor: 3.402

3.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

Review 4.  Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features.

Authors:  Tokujiro Yano; Akira Haro; Yasunori Shikada; Riichiroh Maruyama; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2011-05-13       Impact factor: 3.402

5.  SIFORM: shared informative factor models for integration of multi-platform bioinformatic data.

Authors:  Xuebei An; Jianhua Hu; Kim-Anh Do
Journal:  Bioinformatics       Date:  2016-07-05       Impact factor: 6.937

Review 6.  Lung cancer: epidemiology, etiology, and prevention.

Authors:  Charles S Dela Cruz; Lynn T Tanoue; Richard A Matthay
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

7.  Exon 7 splicing variant of estrogen receptor α is associated with pathological invasiveness in smoking-independent lung adenocarcinoma.

Authors:  Ayumi Suzuki; Katsuhiro Okuda; Motoki Yano; Risa Oda; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Makoto Nakanishi; Ryoichi Nakanishi
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

8.  Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study.

Authors:  Xia Pu; Yuanqing Ye; Margaret R Spitz; Liang Wang; Jian Gu; Scott M Lippman; Michelle A T Hildebrandt; Waun Ki Hong; John D Minna; Jack A Roth; Ping Yang; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2012-09-13       Impact factor: 12.531

9.  Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers.

Authors:  F Xu; H Zhang; Y Su; J Kong; H Yu; B Qian
Journal:  Clin Transl Oncol       Date:  2014-05-08       Impact factor: 3.405

10.  Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer.

Authors:  Seh Jong Park; In Keun Choi; Hee Yun Seo; Hwa Jung Sung; Kyong Hwa Park; Sang Cheul Oh; Jae Hong Seo; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.